Immuneering Announces Participation in February Investor Conferences
Immuneering Corporation (IMRX) will participate in two February investor conferences to discuss the company’s pipeline, platform, and business strategy. The company aims to develop universal-RAS/RAF medicines for broad cancer patient populations. Participating will be the CEO, CSO, CBO, and CAO, discussing the company's progress and future plans. The conferences include Guggenheim 6th Annual Biotechnology Conference and Oppenheimer 34th Annual Healthcare Life Sciences Conference, with live webcasts available on Immuneering’s website.
02/01/2024 - 08:00 AM
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company’s pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Immuneering will participate in the following investor conferences:
Guggenheim 6th Annual Biotechnology Conference (February 7 – 8, 2024) Format: Fireside chat and 1x1 investor meetingsOppenheimer 34 th Annual Healthcare Life Sciences Conference (February 13 – 14, 2024) Format: Virtual presentation and 1x1 investor meetingsThe presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation .
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com .
Media Contact: gina@nugentcommunications.com
Investor Contacts: laurence@gilmartinir.com or
Kiki Patel, PharmDkiki@gilmartinir.com
What is the ticker symbol for Immuneering Corporation?
The ticker symbol for Immuneering Corporation is IMRX.
What is the purpose of Immuneering Corporation's participation in the investor conferences?
Immuneering Corporation will participate in the investor conferences to discuss the company’s pipeline, platform, and business strategy, aiming to develop universal-RAS/RAF medicines for broad cancer patient populations.
Who will be participating in the investor conferences on behalf of Immuneering Corporation?
The CEO, CSO, CBO, and CAO will be participating in the investor conferences on behalf of Immuneering Corporation.
When and where will the Guggenheim 6th Annual Biotechnology Conference take place?
The Guggenheim 6th Annual Biotechnology Conference will take place on February 7 – 8, 2024, and the format will include a fireside chat and 1x1 investor meetings.
When and where will the Oppenheimer 34th Annual Healthcare Life Sciences Conference take place?
The Oppenheimer 34th Annual Healthcare Life Sciences Conference will take place on February 13 – 14, 2024, and the format will include a virtual presentation and 1x1 investor meetings.
Where can the live webcasts of the presentations be accessed?
The live webcasts of the presentations can be accessed on Immuneering’s website at the Events & Presentations section.
